MGS has introduced the A.i.r. Platform, a new customizable auto-injector platform aimed at addressing the varied requirements of patients, pharmaceutical companies, and healthcare providers.
The Auto-injector Reimagined (A.i.r.) Platform is built around an adaptable core engine with patents pending. This engine can be integrated into multiple device formats, allowing companies to develop patient-focused drug delivery devices more quickly and efficiently. The platform accommodates fill volumes from 0.3 to 2.25 mL and supports flexible development paths for different therapeutic needs and brand specifications.
The design allows for significant customization in terms of form, function, and aesthetics. Features such as audible feedback are intended to improve user experience while also reducing development costs and speeding up time to market. Companies can adjust each device to match their specific drug formulations and branding objectives.
Bob Bordignon, SVP of Sales and Marketing at MGS, stated: “The A.i.r. Platform represents a major leap forward in how auto-injectors are developed, customised and scaled. This is exactly the kind of innovation our customers and their patients have been waiting for: flexible, efficient and built to meet the diverse needs of multiple patient groups. Our journey with auto-injectors began many years ago, both in delivering unique designs and manufacturing millions of auto-injector sub-assemblies. We’re excited to offer a paradigm-shifting platform to help our customers get to market faster, with less risk and unprecedented design flexibility.”
Development of the platform incorporated insights from 14 therapeutic areas based on feedback from clinicians, patients, regulatory authorities, and FDA data.
With only seven plastic parts and two springs in its construction, the A.i.r. Platform aims for simplicity by minimizing failure risks while supporting efficient assembly processes that align with sustainability goals.
Martin Hoier Thomsen, Senior Development Engineer and Project Manager at MGS said: “The A.i.r. Platform is the result of years of discovery, engineering and collaborative design and development expertise. It was created to give customers access to more customisation, advanced features and greater flexibility to meet a diverse range of patient needs, including pediatric-focused designs and solutions for users with limited dexterity due to chronic conditions. Pharma companies with drugs in development that require unique delivery solutions can avoid starting from scratch and save years of development time to reduce time to clinic.”
MGS highlights its role as a vertically integrated contract development manufacturing organization (CDMO), providing services across all stages including design & development, tooling, automation, and manufacturing on a global scale.
Bordignon added: “At MGS, we say we’re more than manufacturers, more than consultants – we’re end-to-end partners. What that means is that we’re in it with you to provide the agility, attention and focus you need to achieve your goals and accelerate your time to market,” continued Bordignon. “A.i.r. is an excellent representation of this end-to-end expertise, bringing knowledge together from each of our areas of discipline to produce a best-in-class device that will make a real impact on improving lives.”
